Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABUS

Arbutus Biopharma Corp

Mar 20 • 04:00PM ET

3.31

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN ALNY MRNA VRTX EXEL NBIX BMRN SRPT BLUE

| Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.43	Insider Own	22.38%	Shs Outstand	189.44M	Perf Week	-0.30%
Market Cap	627.22M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-0.18%	Shs Float	147.08M	Perf Month	-2.36%
Income	-76.70M	PEG	-	EPS next Q	-0.07	Inst Own	54.97%	Short Float	5.72%	Perf Quarter	-6.76%
Sales	6.74M	P/S	93.06	EPS this Y	12.50%	Inst Trans	2.77%	Short Ratio	9.67	Perf Half Y	-18.87%
Book/sh	0.56	P/B	5.87	EPS next Y	22.08%	ROA	-51.29%	Short Interest	8.41M	Perf Year	30.31%
Cash/sh	0.67	P/C	4.91	EPS next 5Y	-	ROE	-67.81%	52W Range	2.30 - 4.72	Perf YTD	1.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.41%	ROI	-67.77%	52W High	-29.95%	Beta	1.48
Dividend TTM	-	Quick Ratio	7.02	Sales past 5Y	68.89%	Gross Margin	79.15%	52W Low	43.91%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	7.02	EPS Y/Y TTM	8.60%	Oper. Margin	-1165.03%	RSI (14)	49.84	Volatility	3.45% 5.10%
Employees	73	Debt/Eq	0.06	Sales Y/Y TTM	-69.69%	Profit Margin	-1137.64%	Recom	1.00	Target Price	5.33
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	13.08%	Payout	-	Rel Volume	0.96	Prev Close	3.31
Sales Surprise	-28.00%	EPS Surprise	-6.38%	Sales Q/Q	-71.25%	Earnings	Nov 06 BMO	Avg Volume	870.00K	Price	3.31
SMA20	-0.45%	SMA50	-0.58%	SMA200	-7.74%	Trades		Volume	834,153	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire)
Feb-25-25 07:00AM	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO (GlobeNewswire)
Feb-12-25 09:24AM	Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-16-25 11:22AM	Jim Cramer on Arbutus Biopharma Corporation (ABUS): It Loses Money (Insider Monkey)
Jan-13-25 07:30AM	Arbutus Provides 2025 Corporate and Financial Update (GlobeNewswire)
08:20AM	Loading…
Dec-06-24 08:20AM	Heres Why Arbutus (ABUS) Surged in Q3 (Insider Monkey)
Dec-03-24 08:00AM	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors (Business Wire)
Nov-26-24 07:30AM	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat (GlobeNewswire)
Nov-15-24 11:02AM	Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon (GlobeNewswire)
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
Nov-14-24 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 02:12AM	Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
02:07AM	Q3 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:45AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-24 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
02:30AM	Loading…
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:44AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:25AM	Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 (GlobeNewswire)
Apr-30-24 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Apr-18-24 07:30AM	Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-04-24 08:30AM	Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Mar-08-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-24 08:17AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:14PM	Q4 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
08:40AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 07:30AM	Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jan-08-24 07:30AM	Arbutus Announces 2024 Corporate Objectives and Provides Financial Update (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
09:12AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
01:16AM	Q3 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:05AM	Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:15AM	Arbutus Announces CEO, William Collier, to Retire December 31, 2023 (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-24-23 07:30AM	Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-18-23 07:30AM	Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference (GlobeNewswire) -5.82%
Oct-11-23 08:05AM	Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Sep-12-23 10:56AM	Arbutus BioPharma narrows research focus to extend cash runway (American City Business Journals) -7.73%
08:58AM	Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up (Zacks)
Sep-11-23 04:15PM	Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended (GlobeNewswire)
Sep-07-23 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-04-23 03:29PM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:49AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-23-23 10:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stake (Simply Wall St.)
Jul-20-23 07:30AM	Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jul-12-23 07:30AM	Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors (GlobeNewswire)
Jul-10-23 04:01PM	Arbutus Appoints Two New Executives (GlobeNewswire)
Jun-23-23 09:40AM	Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year? (Zacks)
Jun-21-23 07:30AM	Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody (GlobeNewswire)
02:01AM	Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 (GlobeNewswire)
Jun-07-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
02:01AM	Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 (GlobeNewswire)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-31-23 07:30AM	Arbutus to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 09:26AM	Valneva (VALN) Stock Down 53% in the Past Year: Here's Why (Zacks)
May-29-23 10:08AM	FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug (Zacks)
May-22-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year? (Zacks)
May-17-23 07:38AM	Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation (Simply Wall St.)
May-09-23 12:00PM	Arbutus (ABUS) Upgraded to Buy: Here's Why (Zacks)
07:30AM	Arbutus to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 11:52PM	Q1 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
08:55AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports First Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Apr-27-23 03:20AM	Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 (GlobeNewswire)
Apr-25-23 11:57AM	Why Arbutus Biopharma Stock Is Plunging Today (Benzinga) -12.46%

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sofia Michael J.	Officer	Mar 19 '25	Proposed Sale	3.20	150,000	480,000		Mar 19 09:34 AM
Sofia Michael J.	Officer	Mar 13 '25	Proposed Sale	3.38	100,000	338,000		Mar 13 03:55 PM
Sofia Michael J.	Member of immediate family of	Mar 07 '25	Proposed Sale	3.29	167,162	549,963		Mar 07 02:59 PM
HASTINGS DAVID C	Chief Financial Officer	Feb 04 '25	Sale	3.28	22,183	72,827	159,724	Feb 05 04:02 PM
Sims Karen	Chief Medical Officer	Feb 04 '25	Sale	3.28	19,348	63,519	106,194	Feb 05 04:02 PM
McElhaugh Michael J.	Interim President & CEO	Feb 04 '25	Sale	3.28	23,790	78,103	1,481,003	Feb 05 04:02 PM
Naftzger J. Christopher	General Counsel and CCO	Feb 04 '25	Sale	3.28	11,333	37,206	86,244	Feb 05 04:02 PM
David C. Hastings	Officer	Feb 04 '25	Proposed Sale	3.28	22,183	72,827		Feb 04 08:39 PM
Karen Sims	Officer	Feb 04 '25	Proposed Sale	3.28	19,348	63,519		Feb 04 08:38 PM
Michael J. McElhaugh	Director and Officer	Feb 04 '25	Proposed Sale	3.28	23,790	78,103		Feb 04 08:36 PM
J. Christopher Naftzger	Officer	Feb 04 '25	Proposed Sale	3.28	11,333	37,206		Feb 04 08:34 PM
MANCHESTER KEITH S	Director	Aug 14 '24	Option Exercise	0.56	54,915	30,752	54,915	Aug 16 04:07 PM
MANCHESTER KEITH S	Director	Aug 14 '24	Sale	3.69	8,846	32,637	46,069	Aug 16 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABUS

Arbutus Biopharma Corp

Upgrade your FINVIZ experience